European drugmaker Novartis (NVS), best known for blockbuster drugs like Entresto, Cosentyx, and Kesimpta, just announced a major U.S.

Hikma Pharmaceuticals (OTCPK:HKMPF) announced on Thursday that it has acquired the FDA-approved Abbreviated New Drug ...

Novartis plans to build and expand 10 U.S. facilities New facilities include six manufacturing plants and a research and development site The construction will take place over five years, create ...

Besides, Novartis, Johnson & Johnson plans to spend $55 billion over four years on domestic manufacturing, research and technology. Merck announced plans to spend $1 billion on a vaccine ...

Novartis NVS shares ended the last trading session 4% higher at $107.52. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This ...

Amid renewed threats of import tariffs on pharmaceuticals from the Trump administration, Novartis plans to spend $23 billion over the next five years to expand its manufacturing, research and ...

With new manufacturing capacity, Novartis will be able to produce 100% of its key medicines end-to-end in the US, a significant increase from current levels Increased R&D presence planned includes ...

European drugmaker Novartis (NVS), best known for blockbuster drugs like Entresto, Cosentyx, and Kesimpta, just announced a major U.S. investment. The $200 billion pharma company intends to invest ...

It is the generic version of Mekinist, a branded product developed by Novartis Pharma AG (NYSE:NVS). As part of the deal, Hikma also entered into a commercial agreement with Novugen under which it ...